ALK+ Non-Small Cell Lung Cancer
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
Shirish M. Gadgeel, MD, discusses the phase 1/2 ARROS-1 and ALKOVE-1 studies presented at the ESMO 2024 Congress.
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
Dr. Manochakian discusses the implications of recent phase 3 trials in lung cancer.
Dr. Manochakian discusses the most pressing unanswered questions in lung cancer and how they could be addressed.
Advertisement
Expert Interviews on Lung Cancer
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.